Aims and scope
Epigenetics & Chromatin is a peer-reviewed, open access journal that publishes research, and reviews, providing novel insights into epigenetic inheritance and chromatin-based interactions. The journal aims to understand how gene and chromosomal elements are regulated and their activities maintained during processes such as cell division, differentiation and environmental alteration.
Epigenetic research is concerned with heritable changes that do not change DNA sequence, but rather involve stable modifications of chromatin, DNA or protein conformation, and includes research on non-coding RNAs, nuclear organization and chromatin interactions. Epigenetics is a broad area of research that is important for understanding the basic processes of cellular life, and as such has implications for a wide range of disciplines. The field encompasses studies that use model systems to discover and investigate epigenetic mechanisms and studies of human development with an emphasis on epigenetic mechanisms or chromatin organization.
Epigenetics & Chromatin fulfills the need for a journal that reflects the breadth of epigenetic research. Topics include, but are not limited to, gene silencing and imprinting, nuclear reprogramming, nucleosome modification, remodeling and dynamics, DNA methylation, non-coding RNAs, chromosomal maintenance elements, dosage compensation and nuclear organization. Approaches that apply cutting-edge technologies to problems in the field are especially welcome.
All articles published by Epigenetics & Chromatin are made freely and permanently accessible online immediately upon publication, without subscription charges or registration barriers. Further information about open access can be found here.
As authors of articles published in Epigenetics & Chromatin you are the copyright holders of your article and have granted to any third party, in advance and in perpetuity, the right to use, reproduce or disseminate your article, according to the BioMed Central license agreement.
For those of you who are US government employees or are prevented from being copyright holders for similar reasons, BioMed Central can accommodate non-standard copyright lines. Please contact us if further information is needed.
Open access publishing is not without costs. Epigenetics & Chromatin therefore levies an article-processing charge of £1565.00/$2450.00/€1995.00 for each article accepted for publication, plus VAT or local taxes where applicable.
If the corresponding author's institution participates in our open access membership program, some or all of the publication cost may be covered (more details available on the membership page). We routinely waive charges for authors from low-income countries. For other countries, article-processing charge waivers or discounts are granted on a case-by-case basis to authors with insufficient funds. Authors can request a waiver or discount during the submission process. For further details, see our article-processing charge page.
BMC provides a free open access funding support service to help authors discover and apply for article processing charge funding. Visit our OA funding and policy support page to view our list of research funders and institutions that provide funding for APCs, and to learn more about our email support service.
All articles published in Epigenetics & Chromatin are included in:
- Biological Abstracts
- PubMed Central
- Science Citation Index Expanded
The full text of all articles is deposited in digital archives around the world to guarantee long-term digital preservation. You can also access all articles published by BioMed Central on SpringerLink.
Epigenetics & Chromatin has an Impact Factor of 5.351.
Epigenetics & Chromatin operates a single-blind peer-review system, where the reviewers are aware of the names and affiliations of the authors, but the reviewer reports provided to authors are anonymous.
The benefit of single-blind peer review is that it is the traditional model of peer review that many reviewers are comfortable with, and it facilitates a dispassionate critique of a manuscript.
All manuscripts are reviewed by internationally recognized experts in the field, selected in part from our Editorial Board. Reviews are usually returned within 21 days, and the suitability of a manuscript for publication is assessed solely on criteria of scientific excellence. First and final decisions are made by the Editors-in-Chief.
Epigenetics & Chromatin considers the following types of article: Research, Methodology, and Review. For more specific information, please take a look at our Submission Guidelines.
All manuscripts submitted to Epigenetics & Chromatin should adhere to BioMed Central's editorial policies.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Citing articles in Epigenetics & Chromatin
Articles in Epigenetics & Chromatin should be cited in the same way as articles in a traditional journal. Because articles are not printed, they do not have page numbers; instead, they are given a unique article number.
Article citations follow this format:
Authors: Title. Epigenetics & Chromatin [year], [volume number]:[article number].
e.g. Roberts LD, Hassall DG, Winegar DA, Haselden JN, Nicholls AW, Griffin JL: Increased hepatic oxidative metabolism distinguishes the action of Peroxisome Proliferator-Activated Receptor delta from Peroxisome Proliferator-Activated Receptor gamma in the Ob/Ob mouse. Epigenetics & Chromatin 2009, 1:115.
refers to article 115 from Volume 1 of the journal.
Appeals and complaints
If you wish to appeal a rejection or make a complaint you should, in the first instance, contact the Editor who will provide details of the journal's complaints procedure. For complaints that cannot be resolved with the Editor, the authors should contact the Publisher.
Why publish your article in Epigenetics & Chromatin
Epigenetics & Chromatin's open access policy allows maximum visibility of articles published in the journal as they are available to a wide, global audience.
Speed of publication
Epigenetics & Chromatin offers a fast publication schedule whilst maintaining rigorous peer review; all articles must be submitted online, and peer review is managed fully electronically (articles are distributed in PDF form, which is automatically generated from the submitted files). Articles will be published with their final citation after acceptance, in both fully browsable web form, and as a formatted PDF.
Online publication in Epigenetics & Chromatin gives you the opportunity to publish large datasets, large numbers of color illustrations and moving pictures, to display data in a form that can be read directly by other software packages so as to allow readers to manipulate the data for themselves, and to create all relevant links (for example, to PubMed, to sequence and other databases, and to other articles).
Promotion and press coverage
Articles published in Epigenetics & Chromatin are included in article alerts and regular email updates. Some may be highlighted on Epigenetics & Chromatin’s pages and on the BioMed Central homepage.
In addition, articles published in Epigenetics & Chromatin may be promoted by press releases to the general or scientific press. These activities increase the exposure and number of accesses for articles published in Epigenetics & Chromatin. A list of articles recently press-released by journals published by BioMed Central is available here.
As an author of an article published in Epigenetics & Chromatin you retain the copyright of your article and you are free to reproduce and disseminate your work (for further details, see the BioMed Central license agreement).
For further information about the advantages of publishing in a journal from BioMed Central, please click here.
2017 Journal Metrics
35.0 days to first decision for reviewed manuscripts only
26.3 days to first decision for all manuscripts
90.5 days from submission to acceptance
12.0 days from acceptance to publication
664 Altmetric mentions